Last reviewed · How we verify
Placebo & Aspirin
Placebo & Aspirin is a Antiplatelet agent / NSAID Small molecule drug developed by Baim Institute for Clinical Research. It is currently FDA-approved for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome.
Aspirin inhibits platelet aggregation by irreversibly blocking cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and preventing clot formation.
Aspirin inhibits platelet aggregation by irreversibly blocking cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and preventing clot formation. Used for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome.
At a glance
| Generic name | Placebo & Aspirin |
|---|---|
| Sponsor | Baim Institute for Clinical Research |
| Drug class | Antiplatelet agent / NSAID |
| Target | Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently inactivating them and preventing the synthesis of thromboxane A2 in platelets. This reduces platelet activation and aggregation, thereby decreasing the risk of thrombotic events. The placebo component serves as a control in clinical trials to assess the true efficacy of aspirin.
Approved indications
- Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy (PHASE3)
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (PHASE3)
- Adjuvant Low Dose Aspirin in Colorectal Cancer (PHASE3)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo & Aspirin CI brief — competitive landscape report
- Placebo & Aspirin updates RSS · CI watch RSS
- Baim Institute for Clinical Research portfolio CI
Frequently asked questions about Placebo & Aspirin
What is Placebo & Aspirin?
How does Placebo & Aspirin work?
What is Placebo & Aspirin used for?
Who makes Placebo & Aspirin?
What drug class is Placebo & Aspirin in?
What development phase is Placebo & Aspirin in?
What are the side effects of Placebo & Aspirin?
What does Placebo & Aspirin target?
Related
- Drug class: All Antiplatelet agent / NSAID drugs
- Target: All drugs targeting Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
- Manufacturer: Baim Institute for Clinical Research — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)
- Indication: Drugs for Acute coronary syndrome
- Compare: Placebo & Aspirin vs similar drugs
- Pricing: Placebo & Aspirin cost, discount & access